StromaCare is a pioneer biotech company in the field of Tumoral Stroma biology and role in multiple solid cancers.

StromaCare scientific Team has developed a deep expertise in identifying and understanding tumoral stroma components playing a key role in cancer, as demonstrated by several publications in major international scientific reviews.

StromaCare’s ambition is to develop innovative products in immuno-oncology to :

- Address specifically stromal components promoting tumor growth, immune escape and metastasis

- Modulate the stroma structure to enhance delivery of therapeutic agents at the core of the tumor and facilitate tumor resection surgery.

StromaCare’s first lead product will reach First-in-Human (FIH) clinical trial in 2025.